Experienced in Thrombocytopenia

Xiaojing W. Yan

155 Nanjing North Street, 
Shenyang, CN 
Experienced in Thrombocytopenia
155 Nanjing North Street, 
Shenyang, CN 
OverviewLocationsClinical Research

Overview

Xiaojing Yan practices in Shenyang, China. Yan is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Lymphofollicular Hyperplasia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 55 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Thrombocytopenia.

Locations

155 Nanjing North Street, Shenyang, 110000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2

55 Total Publications

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.
Journal: Cancer biology & medicine
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yan's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile